Biotechnology
Amgen Raises 2026 Outlook as Q3 Revenue Grows 8% to $10.4 Billion
Amgen announced third-quarter 2026 results on November 3, 2026, reporting an 8% year-over-year increase in total revenue to $10.365 billion and raising its full-year revenue and adjusted earnings per share (EPS) outlook. Product sales also rose 8% to $9.883 billion,…
Lupin Launches Raltegravir With 180-Day Exclusivity Eligibility
Lupin announced on November 3, 2026 that it had launched raltegravir tablets USP 600 mg in the United States following U.S. Food and Drug Administration approval of its Abbreviated New Drug Application. The drugmaker said it is the exclusive first-to-file…
Waters Raises 2026 Guidance as Q3 Adjusted EPS Grows 21%
Waters Corporation announced on November 3, 2026 that third-quarter revenue reached $1.767 billion, $14 million above the midpoint of its guidance, and raised its full-year 2026 revenue and adjusted earnings outlook in its quarterly results release. The quarter ended October…
Waters Buys MOBILion to Add Ion Mobility for Proteomics Research
Waters Corporation announced on November 3, 2026 that it had acquired MOBILion Systems, adding high-resolution ion-mobility separation to its mass-spectrometry portfolio and broadening its entry into proteomics. Financial terms were not disclosed. MOBILion’s SLIM technology, short for Structures for Lossless…
Bayer Raises 2026 Outlook as Pharmaceuticals Drive Q3 Growth
Bayer raised its 2026 adjusted earnings and cash-flow targets on November 3, 2026, after Pharmaceuticals drove third-quarter growth. Group sales reached €10.053 billion, up 4.1% as reported and 1.9% after currency and portfolio adjustments, while EBITDA before special items, which…
Ultima Genomics Wins Sequencing Role in Singapore Program
Ultima Genomics announced on November 2, 2026 that its UG200 Sequencing Platform had been selected for SG-INSIGHT, a cohort under Phase III of Singapore’s National Precision Medicine (NPM) program, through a consortium led by Singapore-based clinical laboratory Lucence with QIAGEN.…
CRISPR Therapeutics Q3 CASGEVY Revenue Reaches $99 Million
CRISPR Therapeutics reported third-quarter 2026 results on November 2, 2026 for the quarter ended September 30, 2026, posting CASGEVY revenue of $99 million and a net loss of $111.4 million, compared with a $106.4 million loss a year earlier. The…
Karyopharm Files Chapter 11 and Plans Merger With Ayrmid
Karyopharm Therapeutics announced on November 2, 2026 that it has entered into a Restructuring Support Agreement with its existing lenders and noteholders and other key stakeholders, providing for a merger between Ayrmid Ltd. and a reorganized Karyopharm. To implement the…
InventisBio Nomelcitinib Meets Phase III Endpoints in Plaque Psoriasis
InventisBio Co., Ltd. announced topline results on November 2, 2026, from a registrational Phase III trial of its oral JH2 selective TYK2 inhibitor nomelcitinib (D-2570) in patients with moderate-to-severe plaque psoriasis. The company said the study met both its primary…
Fresenius Signs WuXi Biologics Pact for Up to 37 Biosimilar Candidates
Fresenius SE & Co. KGaA announced on November 2, 2026, that it has entered an exclusive development agreement with WuXi Biologics, a global contract research, development and manufacturing organization, giving Fresenius exclusive access to up to 37 identified biosimilar candidates…
INOVIO’s VOCERYQ Wins FDA Accelerated Approval to Reduce RRP Surgeries
INOVIO announced on October 30, 2026 that the U.S. Food and Drug Administration granted accelerated approval for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis…
Azenta Acquires SynPlexity and Licenses Elegen DNA Technology
Azenta, Inc. announced on October 30, 2026, two strategic investments intended to advance the next phase of growth for its GENEWIZ business: an exclusive licensing agreement with Elegen Corp., a developer of advanced cell-free DNA manufacturing technology, and the acquisition…
Sun Pharma Wins FDA Approval for Ilumya in Active Psoriatic Arthritis
Sun Pharmaceutical Industries announced on October 30, 2026 that the U.S. Food and Drug Administration approved the supplemental Biologics License Application for Ilumya (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis. The approval, set out in the company’s…
Cambrex Starts Construction on $120 Million Iowa API Expansion
Cambrex, a contract development and manufacturing organization based in East Rutherford, New Jersey, announced on October 30, 2026 the groundbreaking of a $120 million expansion at its Charles City, Iowa manufacturing facility. The company said the project will add 160,000…
PTC Therapeutics Raises 2026 Outlook as Q3 Revenue Hits $358 Million
PTC Therapeutics reported financial results for the third quarter ended September 30, 2026, on October 29, 2026, posting total revenues of $357.8 million and raising its full-year 2026 total revenue expectation to a range of $1.29 billion to $1.32 billion.…
